Virginia L Filiaci

Author PubWeight™ 0.92^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.	Gynecol Oncol	2015	0.92